ES2319107T3 - Derivados de 5-halo-triptamina usados como ligandos de los receptores de serotonina 5-ht6 y/o 5-ht7. - Google Patents

Derivados de 5-halo-triptamina usados como ligandos de los receptores de serotonina 5-ht6 y/o 5-ht7. Download PDF

Info

Publication number
ES2319107T3
ES2319107T3 ES02745793T ES02745793T ES2319107T3 ES 2319107 T3 ES2319107 T3 ES 2319107T3 ES 02745793 T ES02745793 T ES 02745793T ES 02745793 T ES02745793 T ES 02745793T ES 2319107 T3 ES2319107 T3 ES 2319107T3
Authority
ES
Spain
Prior art keywords
use according
compounds
formula
useful
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02745793T
Other languages
English (en)
Spanish (es)
Inventor
Maria A. Sigma-Tau Ind. Farm. Riu. SpA DI CESARE
Patrizia Sigma-Tau Ind. Pharma. Riu. SpA MINETTI
Giorgio Sigma-Tau Ind. Pharmac. Riun. SpA TARZIA
Gilberto Sigma-Tau Ind. Pharma. Riu. SpA SPADONI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2319107T3 publication Critical patent/ES2319107T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
ES02745793T 2001-06-21 2002-06-17 Derivados de 5-halo-triptamina usados como ligandos de los receptores de serotonina 5-ht6 y/o 5-ht7. Expired - Lifetime ES2319107T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM01A0356 2001-06-21
IT2001RM000356A ITRM20010356A1 (it) 2001-06-21 2001-06-21 "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.

Publications (1)

Publication Number Publication Date
ES2319107T3 true ES2319107T3 (es) 2009-05-04

Family

ID=11455609

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02745793T Expired - Lifetime ES2319107T3 (es) 2001-06-21 2002-06-17 Derivados de 5-halo-triptamina usados como ligandos de los receptores de serotonina 5-ht6 y/o 5-ht7.

Country Status (21)

Country Link
US (1) US7098233B2 (enExample)
EP (1) EP1404317B1 (enExample)
JP (2) JP4683839B2 (enExample)
KR (1) KR100885308B1 (enExample)
CN (1) CN100482223C (enExample)
AT (1) ATE416767T1 (enExample)
AU (1) AU2002317482B2 (enExample)
BR (1) BR0210538A (enExample)
CA (1) CA2455296C (enExample)
CY (1) CY1108879T1 (enExample)
CZ (1) CZ20033314A3 (enExample)
DE (1) DE60230270D1 (enExample)
DK (1) DK1404317T3 (enExample)
ES (1) ES2319107T3 (enExample)
HU (1) HUP0400250A3 (enExample)
IT (1) ITRM20010356A1 (enExample)
MX (1) MXPA03011510A (enExample)
PL (1) PL367618A1 (enExample)
PT (1) PT1404317E (enExample)
SK (1) SK287828B6 (enExample)
WO (1) WO2003000252A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039127A1 (es) * 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
US8086315B2 (en) 2004-02-12 2011-12-27 Asap Medical, Inc. Cardiac stimulation apparatus and method for the control of hypertension
CA2557158A1 (en) * 2004-02-20 2005-09-01 Astellas Pharma Inc. Prophylactic antimigraine agents
US20080171788A1 (en) * 2005-02-08 2008-07-17 Shinobu Akuzawa Medicament For Irritable Bowel Syndrome
EP1923387B1 (en) 2005-08-08 2011-10-19 Astellas Pharma Inc. Acylguanidine derivative or salt thereof
WO2007046112A1 (en) * 2005-10-19 2007-04-26 Suven Life Sciences Inc. Arylthioether tryptamine derivatives as functional 5-ht6 ligands
WO2007097276A1 (ja) * 2006-02-20 2007-08-30 Astellas Pharma Inc. ピロール誘導体またはその塩
EP2120950B1 (en) * 2007-03-21 2012-07-04 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain
EP2209380A4 (en) * 2007-10-09 2011-09-14 Mark T Hamann METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
CA2842455A1 (en) * 2011-08-05 2013-02-14 Sucampo Ag Method for treating schizophrenia
CN102816103B (zh) * 2012-08-20 2014-05-07 冉瑞琼 硫化天冬氨酸修饰的退黑素衍生物及其应用
US9008769B2 (en) 2012-12-21 2015-04-14 Backbeat Medical, Inc. Methods and systems for lowering blood pressure through reduction of ventricle filling
US9370662B2 (en) 2013-12-19 2016-06-21 Backbeat Medical, Inc. Methods and systems for controlling blood pressure by controlling atrial pressure
CN104529865B (zh) * 2014-12-12 2017-02-01 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
US10342982B2 (en) 2015-09-11 2019-07-09 Backbeat Medical, Inc. Methods and systems for treating cardiac malfunction
US10485658B2 (en) 2016-04-22 2019-11-26 Backbeat Medical, Inc. Methods and systems for controlling blood pressure
CN108926565A (zh) * 2017-05-26 2018-12-04 中国科学院上海生命科学研究院 五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用
EP3813810A4 (en) * 2018-06-21 2022-03-30 Robert John Petcavich METHODS OF INDUCING DENDRITICAL AND SYNAPTIC GENESIS IN CHRONIC NEURODEGENERATIVE DISEASES
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
LT4084791T (lt) * 2020-02-18 2025-02-25 Gilgamesh Pharmaceuticals, Inc. Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
WO2021116503A2 (en) * 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
WO2022061196A1 (en) * 2020-09-18 2022-03-24 Mydecine Innovations Group Inc. Novel formulations of psilocybin and psilocin compounds as serotonin agonists in combination with 3,4 methylenedioxymethamphetamine (mdma)
KR20240013170A (ko) 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태
IL309210A (en) 2021-06-09 2024-02-01 Atai Therapeutics Inc Parent drugs and conjugates of dimethyltryptamine
US20240343692A1 (en) * 2021-08-09 2024-10-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Selective psychedelic compounds
CA3238440A1 (en) * 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
CN114573578B (zh) * 2022-02-16 2023-11-17 烟台宁远药业有限公司 一种烷基取代氮杂吲哚的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825734A (en) * 1955-04-11 1958-03-04 Upjohn Co Reduction of carbonylic radicals in indolyl-3 compounds
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
FR2315277A1 (fr) * 1975-06-25 1977-01-21 Anvar Nouveaux derives pentacycliques, leur preparation et les compositions qui les contiennent
US4428877A (en) * 1978-07-12 1984-01-31 Richter Gedeon Vegyeszeti Gyar Rt. Cis-10-bromo-E-homoeburnanes
GB8531612D0 (en) * 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
US5300645A (en) * 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
FR2712591B1 (fr) * 1993-11-19 1996-02-09 Pf Medicament Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique.
US5688807A (en) * 1994-03-11 1997-11-18 Eli Lilly And Company Method for treating 5HT2B receptor related conditions
US5504101A (en) * 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
WO1998000400A1 (en) * 1996-06-28 1998-01-08 Meiji Seika Kaisha, Ltd. Tetrahydrobenzindole compounds
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
AU767009B2 (en) * 1998-12-11 2003-10-30 Virginia Commonwealth University Selective 5-HT6 receptor ligands
US6403808B1 (en) * 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
EP1173432B9 (en) * 1999-04-21 2008-10-15 NPS Allelix Corp. Piperidine-indole compounds having 5-ht6 affinity
AU779832B2 (en) 1999-08-12 2005-02-10 Nps Pharmaceuticals, Inc. Azaindoles having serotonin receptor affinity
WO2004041781A1 (en) * 2002-11-07 2004-05-21 Suven Life Sciences Limited Preparation of 3-aminoalkyl-substituted indole derivatives from phenylhydrazines and aminoketones

Also Published As

Publication number Publication date
DE60230270D1 (de) 2009-01-22
PT1404317E (pt) 2009-02-23
BR0210538A (pt) 2004-06-22
CY1108879T1 (el) 2014-07-02
KR100885308B1 (ko) 2009-02-24
AU2002317482B2 (en) 2007-08-16
ITRM20010356A1 (it) 2002-12-23
CZ20033314A3 (cs) 2004-08-18
DK1404317T3 (da) 2009-02-23
HUP0400250A2 (hu) 2004-08-30
JP2011016835A (ja) 2011-01-27
CA2455296C (en) 2010-08-17
WO2003000252A1 (en) 2003-01-03
JP4683839B2 (ja) 2011-05-18
MXPA03011510A (es) 2004-03-18
HK1068792A1 (zh) 2005-05-06
JP2004534816A (ja) 2004-11-18
ITRM20010356A0 (it) 2001-06-21
SK382004A3 (en) 2004-05-04
CA2455296A1 (en) 2003-01-03
SK287828B6 (sk) 2011-11-04
PL367618A1 (en) 2005-03-07
US7098233B2 (en) 2006-08-29
EP1404317A1 (en) 2004-04-07
KR20040032113A (ko) 2004-04-14
US20040235899A1 (en) 2004-11-25
CN1535146A (zh) 2004-10-06
ATE416767T1 (de) 2008-12-15
EP1404317B1 (en) 2008-12-10
CN100482223C (zh) 2009-04-29
HUP0400250A3 (en) 2008-03-28

Similar Documents

Publication Publication Date Title
JP4683839B2 (ja) ５−ｈｔ６および／または５−ｈｔ７セロトニン受容体のリガンドとして使用される５−ハロ−トリプタミン誘導体
AU2002317482A1 (en) 5-halo-tryptamine derivatives used as ligands of the 5-HT6 and/or 5-HT7 serotonin receptors
JP4671123B2 (ja) 新規三環性複素環化合物
ES2464157T3 (es) Remedios para enfermedades causadas por contracción o dilatación vascular
CN102292338B (zh) 酪氨酸激酶蛋白受体拮抗剂
ES2885049T3 (es) Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
BR112013000783A2 (pt) derivados arilamídicos tendo propriedades antiandrogênicas
BR112015014097A2 (pt) compostos químicos
WO2005047286A1 (ja) スピロ複素環化合物
TW200902003A (en) Quinolone and tetrahydroquinoline and related compounds having NOS inhibitory activity
JP2011503120A (ja) 内臓痛を治療するためのインドール化合物および方法
PT2318375E (pt) Imidazole carboxamidas
BR112020018933A2 (pt) Composto, composição farmacêutica, método de tratamento de um transtorno associado a kv7 e método de tratamento de um transtorno associado a uma mutação kcnq2
ES2222828B1 (es) Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos.
JP4467307B2 (ja) ５−ｈｔ受容体アンタゴニストとしてのピリジルスルホン誘導体
BR112017025023B1 (pt) Compostos heterocíclicos de carbamato de 3,3-difluoropiperidina, seu uso como antagonistas do receptor nmda nr2b e composição farmacêutica que os compreende
TW202340145A (zh) 氘化有機化合物及其用途
CN101137655A (zh) 雄激素受体调节剂化合物和方法
ES2866324T3 (es) Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria
BR112020008371A2 (pt) novos derivados de alcoxiamino para tratamento de dor e condições relacionadas à dor
HK1068792B (en) 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors
BRPI0616462A2 (pt) Composto; composição; método para o tratamento ou prevenção de uma condição melhorada pela recaptação de monoamina em um sujeito necessitado; e seus usos
CA2429969A1 (en) Substituted indolines as 5-ht receptor ligands
JP2002502362A (ja) カッパー作動因子及びその薬理製剤